nach oben

Erschienen in:

19.04.2021 | Schwerpunkt

Schwerpunkt "Zelluläre Therapien"

Allogene Blutstammzelltransplantation: Etabliertes und Neues

verfasst von: Dr. med. Alessia Fraccaroli, Elena Stauffer, Prof. Dr. med. Dr. rer. nat. Michael von Bergwelt-Baildon, PD Dr. med. Johanna Tischer

Erschienen in: InFo Hämatologie + Onkologie | Ausgabe 4/2021

Einloggen, um Zugang zu erhalten

Auszug

Die allogene Blutstammzelltransplantation ist das älteste zelltherapeutische Verfahren, das in der Therapie von hämatologischen Erkrankungen gut etabliert und wirksam ist. Modifizierte Behandlungskonzepte erlauben zunehmend auch die Behandlung von Patienten mit rezidivierten/refraktären Erkrankungen, auch bei Patienten ohne HLA-kompatiblen Blutstammzellspender und bei älteren Patienten. Dieser Beitrag liefert einen Überblick über das Verfahren und seinen Ablauf sowie über wichtige Komplikationen und beinhaltet einen Ausblick auf neuere Entwicklungen. …

Robert C. A decade of immune-checkpoint inhibitors in cancer therapy. Nat Commun. 2020;11(1):3801

Srivastava S, Riddell SR. Engineering CAR-T cells: Design concepts. Trends Immunol. 2015;36(8):494-502

Baeuerle PA, Reinhardt C. Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res. 2009;69(12):4941-4

Thomas ED et al. Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. N Engl J Med. 1957;257(11):491-6

Mathe G et al. Successful allogenic bone marrow transplantation in man: chimerism, induced specific tolerance, and possible anti-leukemic effects. Blood. 1965;25:179-96

Horowitz MM et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990;75(3):555-62

Kolb HJ et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood. 1995;86(5):2041-50

Kolb HJ. Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood. 2008;112(12):4371-83

Schmid C et al. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. J Clin Oncol. 2007;25(31):4938-45

10.

Sorror ML et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106(8):2912-9

11.

Finke J et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol. 2009;10(9):855-64

12.

Hilgendorf I et al. Long-term follow-up after allogeneic stem cell transplantation. Dtsch Arztebl Int. 2015;112(4):51-8

13.

Savani BN et al. How I treat late effects in adults after allogeneic stem cell transplantation. Blood. 2011;117(11):3002-9

14.

Richardson PG et al. Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial. Biol Blood Marrow Transplant. 2010;16(7):1005-17

15.

Zeiser R. Introduction to a How I Treat series on major complications after allogeneic stem cell transplantation. Blood. 2020;135(19):1609

16.

Jagasia M et al. Randomized controlled study of ECP with methoxsalen as first-line treatment of patients with moderate to severe cGVHD. Blood Adv. 2019;3(14):2218-29

17.

Saria MG, Gosselin-Acomb TK. Hematopoietic stem cell transplantation: implications for critical care nurses. Clin J Oncol Nurs. 2007;11(1):53-63

18.

Tischer J et al. Virus infection in HLA-haploidentical hematopoietic stem cell transplantation: incidence in the context of immune recovery in two different transplantation settings. Ann Hematol. 2015;94(10):1677-88

19.

Hubmann M et al. Occurrence, risk factors and outcome of adenovirus infection in adult recipients of allogeneic hematopoietic stem cell transplantation. J Clin Virol. 2016;82:33-40

20.

Peterson L et al. Reactivation of polyomavirus in the genitourinary tract is significantly associated with severe GvHD and oral mucositis following allogeneic stem cell transplantation. Infection. 2016; 44(4):483-90

21.

Moosmann A et al. Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells. Blood. 2010;115(14):2960-70

22.

Feuchtinger T et al. Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation. Blood. 2010;116(20):4360-7

23.

Zeiser R et al. Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease. N Engl J Med. 2020;382(19):1800-10

24.

Rahmat LT, Logan AC. Ibrutinib for the treatment of patients with chronic graft-versus-host disease after failure of one or more lines of systemic therapy. Drugs Today (Barc). 2018;54(5):305-13

25.

Mielke S et al. Salvage therapy with everolimus reduces the severity of treatment-refractory chronic GVHD without impairing disease control: a dual center retrospective analysis. Bone Marrow Transplant. 2014;49(11):1412-8

26.

Kuzmina Z et al. Significantly worse survival of patients with NIH-defined chronic graft-versus-host disease and thrombocytopenia or progressive onset type: results of a prospective study. Leukemia. 2012;26(4):746-56

27.

Schmid C et al. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol. 2005;23(24):5675-87

28.

Luznik L, Fuchs EJ. High-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantation. Immunol Res. 2010;47(1-3):65-77

29.

Luznik L et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008;14(6):641-50.

30.

Tischer J et al. Feasibility of clofarabine cytoreduction followed by haploidentical hematopoietic stem cell transplantation in patients with relapsed or refractory advanced acute leukemia. Ann Hematol. 2013;92(10):1379-88

31.

Fraccaroli A et al. Sequential HLA-haploidentical transplantation utilizing post-transplantation cyclophosphamide for GvHD prophylaxis in high-risk and relapsed/refractory AML/MDS. Am J Hematol. 2018;93(12):1524-31

32.

Zoellner AK et al. Sequential therapy combining clofarabine and T-cell-replete HLA-haploidentical haematopoietic SCT is feasible and shows efficacy in the treatment of refractory or relapsed aggressive lymphoma. Bone Marrow Transplant. 2015;50(5):679-84

33.

Bashey ZA et al. Comparison of outcomes following transplantation with T-replete HLA-haploidentical donors using post-transplant cyclophosphamide to matched related and unrelated donors for patients with AML and MDS aged 60 years or older. Bone Marrow Transplant. 2018;53(6):756-63

34.

Fraccaroli A et al. Favorable Outcome of Sequential HLA-Haploidentical Transplantation Using Ptcy As GvHD Prophylaxis in High Risk AML and MDS of the Elderly. Blood. 2018;132(Supplement 1):3458

35.

36.

Burchert A et al. Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3-Internal Tandem Duplication Mutation (SORMAIN). J Clin Oncol. 2020;38(26):2993-3002

37.

Dominietto A et al. Donor lymphocyte infusions for the treatment of minimal residual disease in acute leukemia. Blood. 2007;109(11):5063-4

38.

Krishnamurthy P et al. Outcome of donor lymphocyte infusion after T cell-depleted allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndromes. Biol Blood Marrow Transplant. 2013;19(4):562-8

39.

Schroeder TM et al. Treatment of MDS, AML and CMML Relapse after Allogeneic Blood Stem Cell Transplantation with Azacitidine, Lenalidomide and Donor Lymphocyte Infusions Results from the Second Interim Analysis of the Prospective Azalena-Trial (NCT02472691). Blood. 2018;132(Supplement 1):703

40.

Schroeder T et al. Treatment of relapsed AML and MDS after allogeneic stem cell transplantation with decitabine and DLI-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group. Ann Hematol. 2018;97(2):335-42

41.

Schuler E et al. Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group. Ann Hematol. 2021;100(4):959-68

42.

Christopeit M et al. Second allograft for hematologic relapse of acute leukemia after first allogeneic stem-cell transplantation from related and unrelated donors: the role of donor change. J Clin Oncol. 2013;31(26):3259-71

43.

Tischer J et al. Second haematopoietic SCT using HLA-haploidentical donors in patients with relapse of acute leukaemia after a first allogeneic transplantation. Bone Marrow Transplant. 2014;49(7):895-901

Titel: Schwerpunkt "Zelluläre Therapien"
Allogene Blutstammzelltransplantation: Etabliertes und Neues
verfasst von: Dr. med. Alessia Fraccaroli
Elena Stauffer
Prof. Dr. med. Dr. rer. nat. Michael von Bergwelt-Baildon
PD Dr. med. Johanna Tischer
Publikationsdatum: 19.04.2021
Verlag: Springer Medizin
Erschienen in: InFo Hämatologie + Onkologie / Ausgabe 4/2021
Print ISSN: 2662-1754
Elektronische ISSN: 2662-1762
DOI: https://doi.org/10.1007/s15004-021-8646-2

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Allogene Blutstammzelltransplantation: Etabliertes und Neues

Auszug

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Update Onkologie

Springer Medizin

Auszug

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2021

RCT zur Radiatio gegen COVID-19

Sotorasib als mögliche neue zielgerichtete Therapie KRAS-G12C-mutierter Tumoren

Apixaban und Blutungsrisiko

Patientendaten ohne Karte einlesen

Komorbiditäten berücksichtigen

Gutes Ansprechen unter Sotorasib

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Update Onkologie